The Trust does not record electronically the number of patients who are treated by laser for a condition.

Size: px

Start display at page:

Download "The Trust does not record electronically the number of patients who are treated by laser for a condition."

Warren Arnold
6 years ago
Views:

1 Ref: FOI/CAD/ID April 20 Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME 9QQ Freedom of Information Act 2000 I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to diseases of the eye and treatment options and volumes. The total patients treated with the following conditions: Wet age-related macular degeneration (AMD) Diabetic macular oedema (DMO) Macular oedema secondary to retinal vein occlusion, branch (branch RVO) Macular oedema secondary to retinal vein occlusion, central (central RVO) Myopic choroidal neovascularization (mcnv) The volume of use of the following treatment options: Ranibizumab Bevacizamab Aflibercept Dexamethasone intravitreal implant Fluocinolone acetonide intravitreal implant Laser Therapy I would like this information for the period March 20 to February 20, broken down by month The Trust does not record electronically the number of patients who are treated by laser for a condition. Please see the tables below: Chairman: Tony Jones Chief Executive: Glenn Douglas Trust Headquarters: Maidstone Hospital, Hermitage Lane, Maidstone, Kent ME 9QQ Telephone: / Fax:

2 Maidstone and Tunbridge Wells NHS Name of Hospital Trust Trust wamd (Wet Age Related Macular Degeneration) Ranibizumab Bevacizumab Aflibercept brvo (Branch Retinal Vein Occlusion) Ranibizumab Bevacizumab <5 <5 <5 <5 <5 <5 Aflibercept <5 <5 <5 <5 <5 <5 Dexamethasone intravitreal implant <5 5 5 <5 <5 <5 <5 <5 <5 <5 <5 crvo (Central Retinal Vein Occlusion) Ranibizumab Bevacizumab <5 <5 <5 <5 Aflibercept <5 <5 < < Dexamethasone intravitreal implant < < <5 <5 7 <5 DMO (Diabetic Macular Oedema) Ranibizumab Bevacizumab <5 <5 <5 Aflibercept Dexamethasone intravitreal implant <5 <5 <5 Chairman: Tony Jones Chief Executive: Glenn Douglas Trust Headquarters: Maidstone Hospital, Hermitage Lane, Maidstone, Kent ME 9QQ Telephone: / Fax:

3 Fluocinolone acetonide intravitreal implant 6 <5 <5 <5 <5 <5 <5 <5 <5 mcnv (myopic choroidal neovascularization) Ranibizumab <5 Bevacizumab <5 <5 <5 Aflibercept Name of treatment Hospital Maidstone and Tunbridge Wells NHS Trust wamd (Wet Age Related Macular Degeneration Ranibizumab Bevacizumab Aflibercept brvo (Branch Retinal Vein Occlusion) Ranibizumab Bevacizumab Aflibercept Dexamethasone intravitreal implant crvo (Central Retinal Vein Occlusion) Ranibizumab Bevacizumab Aflibercept Dexamethasone intravitreal implant

4 DMO (Diabetic Macular Oedema) Ranibizumab Bevacizumab Aflibercept Dexamethasone intravitreal implant Fluocinolone acetonide intravitreal implant mcnv (myopic choroidal neovascularization) Ranibizumab Lucentis) 1 1 Bevacizumab Aflibercept

5 Chairman: Tony Jones Chief Executive: Glenn Douglas Trust Headquarters: Maidstone Hospital, Hermitage Lane, Maidstone, Kent ME 9QQ Telephone: / Fax:

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Adult hearing services.

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Adult hearing services. Ref: FOI/CAD/ID 2831 06 April 2016 Please reply to: FOI Administrator Trust Management Service Centre Maidstone Hospital Hermitage Lane Maidstone Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net Freedom of